IL17A and Opportunistic infection: In phase III trials for hidradenitis suppurativa, Kimball et al. demonstrated that the dual IL-17A/F inhibitor bimekizumab achieved a 52% HiSCR50 response rate, yet elevated risks of oral candidiasis and opportunistic infections highlighted the need for immune status-based dosing optimization (98).